Laurus Labs operates as a science-led pharmaceutical and biotechnology company, leading in the production of APIs across various therapeutic areas. The company has shown a strong H1 performance in fiscal year 2026, generating revenues of ₹3,223 Crore, marking a 33% growth year-on-year, driven by both generics and CDMO expansion.

With a significant ₹818 Crore EBITDA, Laurus Labs Limited achieved a 25.4% margin, supported by improved operational execution and product mix. This, coupled with strong gross margin expansion of over 4.5 percentage points, underscores the financial prudence and strategic priorities.

The company's CAPEX spending represents 15% of revenues, reflecting a strong commitment to scaling its manufacturing and R&D infrastructure. Such forward-looking investments are crucial in positioning Laurus favorably for future growth, especially in high-value sectors.

Notable strategic moves include a $600 million investment in a new pharma complex in Vizag, and securing a strategic investment in Aarvik Therapeutics, focusing on Antibody-drug conjugates (ADC) technology. These initiatives align with Laurus Labs' mission to enhance its technology offerings while expanding its global footprint.